Myeloma Patients Europe (MPE) will hold a webinar on Minimal Residual Disease (MRD) in myeloma and related diseases on Monday 20 April 2020 from 18:00 – 19:00 CET.

The webinar will be given by Paula van Hennik, Committee for Medicinal Products for Human Use (CHMP) member at the European Medicine Agency (EMA) who will give a 40-minute presentation on MRD and its role in myeloma and AL amyloidosis patients. The session will be followed by a 20-minute Q&A session.

This webinar is part of the MPE AGM Webinar series, an educational programme planned to replace the Masterclass included in the MPE Annual General Meeting (AGM), which was cancelled due to the outbreak of the COVID-19 (coronavirus) infection. The agenda for the Masterclass involved a wide-range of expert speakers on topics from myeloma and AL amyloidosis updates through to medicines regulation and health technology assessment. MPE is committed to delivering this programme of education through webinars, so please keep an eye out for further announcements in the coming weeks.

Registration is free of charge. Feel free to forward the registration link to colleagues and other patient advocates who might be interested in attending the webinar. Should you be unable to attend the webinar, please feel free to send your questions in advance to info@mpeurope.org and we will make sure they reach our speaker.

A recording of the webinar will be available shortly after the session.

We look forward to your participation.